Tivic Health Systems マネジメント

マネジメント基準チェック /44

Tivic Health Systemsの CEO はJennifer Ernstで、 Sep2016年に任命され、の在任期間は 8.17年です。の年間総報酬は$ 329.34Kで、 83.5%給与と16.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.15%を直接所有しており、その価値は$ 3.10K 。経営陣と取締役会の平均在任期間はそれぞれ5.7年と5.3年です。

主要情報

Jennifer Ernst

最高経営責任者

US$329.3k

報酬総額

CEO給与比率	83.5%
CEO在任期間	8.2yrs
CEOの所有権	0.1%
経営陣の平均在職期間	5.7yrs
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Oct 17

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Jul 15

CEO報酬分析

Tivic Health Systems の収益と比較して、Jennifer Ernst の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$6m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$329k	US$275k	-US$8m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$419k	US$275k	-US$10m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$249k	US$218k	-US$8m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$197k	US$181k	-US$4m
Dec 31 2019	US$226k	US$210k	-US$4m

報酬と市場: Jenniferの総報酬 ($USD 329.34K ) は、 US市場 ($USD 647.72K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Jenniferの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jennifer Ernst (56 yo)

8.2yrs

在職期間

US$329,340

報酬

Ms. Jennifer Ernst is a Co-Founder, CEO and Director of Tivic Health Systems, Inc. since September 2016 and was its Chief Financial Officer from September 2016 to July 2021. Ms. Ernst served as Chief Strat...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jennifer Ernst	Co-Founder	8.2yrs	US$329.34k	0.15% $ 3.1k
Blake Gurfein	Chief Scientific Officer	5.7yrs	US$405.02k	0.015% $ 308.7
Lisa Wolf	Interim Chief Financial Officer	less than a year	データなし	データなし

5.7yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: TIVCの経営陣は経験豊富で経験豊富です（平均在職期間は5.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Jennifer Ernst	Co-Founder	8.2yrs	US$329.34k	0.15% $ 3.1k
Sheryle Bolton	Independent Chair of the Board	5.3yrs	US$65.12k	0% $ 0
Christina Valauri	Director	less than a year	データなし	データなし
Dean Zikria	Independent Director	5.3yrs	US$37.12k	0% $ 0

5.3yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: TIVCの取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

Tivic Health Systems マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Enrollment Complete in Tivic Health Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Second quarter 2024 earnings released: US$0.32 loss per share (vs US$7.16 loss in 2Q 2023)

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

First quarter 2024 earnings released: US$1.01 loss per share (vs US$10.52 loss in 1Q 2023)

Tivic Health Systems, Inc. to Report Q1, 2024 Results on May 15, 2024

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (Vns); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$10.40 loss per share (vs US$104 loss in FY 2022)

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc. Announces Launch of Second Generation of Tivic ClearUP

Third quarter 2023 earnings released: US$1.48 loss per share (vs US$26.70 loss in 3Q 2022)

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Second quarter 2023 earnings released: US$0.072 loss per share (vs US$0.31 loss in 2Q 2022)

Tivic Health Systems, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Tivic Health Systems, Inc. ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2022)

Tivic Health Systems, Inc. to Report Q1, 2023 Results on May 15, 2023

Tivic Health Launches B2b Portal, Accelerates Healthcare Commercial Sales Expansion

Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.90 loss in 3Q 2021)

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Tivic Health Systems, Inc. (NasdaqCM:TIVC) entered into an Asset Purchase Agreement to acquire Substantially all of the assets, and certain specified liabilities, of Reliefband Technologies, LLC for $33.5 million.

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.49 loss in 2Q 2021)

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.55 loss in 1Q 2021)

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. to Report Q4, 2021 Results on Apr 19, 2022

Tivic Health Systems, Inc. Appoints Sanjay Ahuja, as Senior Vice President, Quality Assurance & Regulatory Affairs

Full year 2021 earnings released: US$2.43 loss per share (vs US$1.58 loss in FY 2020)

Tivic Health Systems, Inc. Collaborates With Leading Medical Research Hospital on First Controlled Trial to Extend Tivic’s Bioelectronic Platform

High number of new and inexperienced directors

No independent directors

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44